Insight on Financial & Corporate Actions - Report on PTC Therapeutics, Inc.

Jul 22, 2015, 09:15 ET from

NEW YORK, July 22, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on PTC Therapeutics, Inc. (NASDAQ: PTCT). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL:

Highlights from our PTCT Report include:

  • Strong First Quarter 2015 Results: In a press release dated May 4, 2015, PTC Therapeutics, Inc. reported about its corporate actions and financial results for the first quarter 2015. During the quarter, total revenues amounted to c. $7.5 million, including $5.1 million in Translarna product sales revenue and $2.4 million in grants and collaborations revenue, compared to total revenue of c. $9.2 million reported in Q1 2014. This decrease in total revenue was due to recognition of a $7.5 million milestone payment from Roche in Q1 2014 related to PTC Therapeutics' SMA collaboration, partially offset by Translarna product sales. Net loss came in at $37.9 million compared to a net loss of $14.1 million in Q1 2014.
  • Ongoing clinical trials lifts R & D expenditure in Q1 2015 - The Company's Research and development expenses were $27.9 million, including $4.7 million in non-cash, stock-based compensation expense, compared to $15.9 million in Q1 2014, including $1.9 million in non-cash, stock-based compensation expense. The Company has attributed this increase in R&D expense to additional costs incurred during the ongoing clinical trials and supply chain activities in support of the launch of Translarna as well as in conjunction with its expanding clinical-stage pipeline.
  • Expected Trial Results and Planned Commercial Launch- On Operational front, the Company highlighted that it aims to release the top-line data from its ongoing Phase 3 ACT DMD trial by Q4 2015 and it expects the results to form the basis for finalizing its New Drug Application for the approval of Translarna in nonsense mutation DMD. Additionally, the Company has also begun working upon its US commercial team and infrastructure in preparation for a potential US launch in the first half of 2016. PTC Therapeutics also aims to file for approval of Translarna for the treatment of nonsense mutation cystic fibrosis in the EU in the second half of 2015.
  • Clinical trials on track - PTC plans to initiate a Phase 2 proof-of-concept study in nonsense mutation aniridia by the end of 2015. PTC is also commencing a proof-of-concept Phase 2 study of Translarna in nonsense mutation MPS I in addition to its ongoingPhase 3 trials in nonsense mutation DMD and nonsense mutation CF. According to the Company, due to its mechanism of action, Translarna has the potential to address numerous disorders caused by a nonsense mutation. The Company continues to evaluate additional indications to fully capture Translarna's potential.

To find out how this influences our rating on PTC Therapeutics, Inc., read the full report in its entirely here:

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.